Abstract: Lentiviral vectors modified at the 5? LTR or both the 5? and 3? LTR's are useful in the production of recombinant lentivirus vectors. Such vectors can be produced in the absence of a functional tat gene. Multiple transformation of the host cell with the vector carrying the transgene enhances virus production.
Type:
Grant
Filed:
July 26, 2006
Date of Patent:
September 30, 2014
Assignee:
GBP IP, LLC
Inventors:
Luigi Naldini, Thomas Dull, Deborah A. Farson, Rochelle Witt
Abstract: Lentiviral vectors modified at the 5? LTR or both the 5? and 3? LTR are useful in the production of recombinant lentivirus vectors (See the Figure). Such vectors can be produced in the absence of a functional tat gene. Multiple transformation of the host cell with the vector carrying the transgene enhances virus production. The vectors can contain inducible or conditional promoters.
Type:
Grant
Filed:
July 20, 2007
Date of Patent:
February 18, 2014
Assignee:
GBP IP, LLC
Inventors:
Luigi Naldini, Thomas Dull, Anatoly Bukovsky, Deborah A. Farson, Rochelle Witt
Abstract: Recombinant lentiviruses and transfer vectors for transgene delivery as well as methods for gene therapy using such vectors are disclosed. The invention provides a third generation lentiviral packaging system and a set of vectors for producing recombinant lentiviruses, as well as novel tissue specific enhancer and promoter elements useful for optimizing liver specific transgene delivery. The transgene is preferably a blood clotting factor such as human factor IX (hFIX) or human factor VIII (hFVIII) and can be used for treatment of hemophilia.
Type:
Grant
Filed:
January 23, 2007
Date of Patent:
June 29, 2010
Assignee:
GBP IP, LLC
Inventors:
James G. McArthur, Dale J. Talbot, Andrew D. Simmons, Ryan McGuinness, Michael Kelly, Lisa V. Tsui, Thomas Dull